摘要
目的探究^(125)Ⅰ粒子植入术联合经肝动脉化疗栓塞(TACE)治疗大肝癌的效果及生存率情况。方法选取2010年1月-2012年1月湘南学院附属医院收治的80例经CT或DSA确诊为大肝癌的患者,按随机数表法分为对照组和观察组,每组各40例。观察组患者采取TACE联合碘-125粒子植入术治疗,对照组患者仅行TACE术治疗。观察两组患者术后甲胎蛋白(AFP)、肝功能指标变化情况,比较两组患者治疗后的临床效果、平均生存期、生存率及预后情况。结果对照组、观察组患者的有效率分别为67.5%、90.0%,观察组明显高于对照组(P<0.05);术后6个月两组患者血清AFP检测水平较术前明显降低(P<0.05),观察组患者术后6个月的血清AFP含量为(86.4±35.5)ng/mL,其明显低于对照组(P<0.05);两组患者术前及术后6个月的肝功能指标比较差异均无统计学意义(P>0.05);观察组术后6个月远处转移的发生率为5.0%,明显低于对照组(P<0.05),术后平均生存期为(19.2±2.1)个月,术后1、2、3年内生存率分别为62.5%、45.0%、32.5%,均明显高于对照组(P<0.05);两组患者随访期间均未出现严重并发症。结论^(125)Ⅰ粒子植入术与TACE联合治疗大肝癌的效果确切,不仅能缓解临床症状,提高局部控制率,还能有效提高生存率,是一种安全性、可行性较高的方法。
Objective To explore the ^125I seed implantation combined with transcatheter arterial ehemoembolization （TACE） therapy on survival and prognosis of patients with large liver cancer. Methods 80 patients with HCC diagnosed by CT or DSA in the Affiliated Hospital of Xiangnan University from January 2010 to January 2012 were selected and randomly divided into control group and observation group, with 40 cases in each group. Patients in observation group were treated with TACE combined with -125 particles implantation, and the control group was treated with TACE. The changes of AFP and liver function in two groups were observed, the clinical effect, the average survival time, survival rate and prognosis of the two groups after treatment were compared. Results The effective rate of the control group and the observation group was 67.5% and 90.0% respectively,, and the observation group was significantly higher than that of the control group （P 〈 0.05）; 6 months after operation, the serum level of alpha-fetoprotein （AFP） was significantly lower than that of the two groups （P 〈 0.05）. The serum AFP content of the observation group was （86.4± 35.5） ng/mL, significantly lower than that of the control group （P 〈 0.05）. The liver function indexes before operation and after operation for 6 months were not statistically significant （P 〉 0.05）. The incidence of distant metastasis in the observation group was 5.0%, significantly lower than that of the control group （P 〈 0.05）, and the average survival time was （19.2±2.1） months, within 1 year, 2 year, 3 year survival rate was 62.5%, 45.0%, 32.5%, which were significantly higher than those of the control group （P 〈 0.05）. Both groups had no serious complications during the follow-up period （P 〉 0.05）. Conclusion ^125I seed implantation efficacy of combination therapy with TACE of large hepatocellular carcinoma exact not only can relieve symptoms, improve the local control rate, but also effectively enhance survival rate,
出处
《中国医药导报》
CAS
2016年第2期73-77,共5页
China Medical Herald
基金
湖南省卫生厅科研项目(B2012-075)
湖南省郴州市科技局科研项目(CZ2014050)
关键词
^125I粒子植入术
肝动脉化疗栓塞术
大肝癌
生存率
Iodine-125 seed implantation
Hepatic arterial chemoembolization
Large liver cancer
Survival rate
